Alexandra Serris Amani Ouedrani Fabrice Uhel Marianne Gazzano Vincent Bedarida Claire Rouzaud Marie-Elisabeth Bougnoux Jean-Herlé Raphalen Sylvain Poirée Olivier Lambotte Guillaume Martin-Blondel Fanny Lanternier
10.3389/fimmu.2022.900522
Front Immunol
2022 Jun 1;13:900522.
anti-pd 1 cerebral mucormycosis covid-associated pulmonary aspergillosis immunotherapy invasive fungal disease
CC BY
https://pubmed.ncbi.nlm.nih.gov/35720319/
COVID-19 Drug Treatment COVID-19 / complications Mucormycosis / complications Mucormycosis / drug therapy Pulmonary Aspergillosis
COVID-19 Drug Treatment COVID-19 / complications Mucormycosis / complications Mucormycosis / drug therapy Pulmonary Aspergillosis Case Reports Antifungal Agents / therapeutic use Humans Immune Checkpoint Inhibitors / therapeutic use Interferon-gamma / therapeutic use Antifungal Agents Immune Checkpoint Inhibitors Interferon-gamma
PMC9199385
35720319
Case Report: Immune Checkpoint Blockade Plus Interferon-Γ Add-On Antifungal Therapy in the Treatment of Refractory Covid-Associated Pulmonary Aspergillosis and Cerebral Mucormycosis
2022